YOU ARE NOW CONNECTED TO THE TOXLINE (1981 FORWARD, NON-ROYALTY) FILE. ==HEMANGIOPERICYTOMA AND ADRIAMYCIN== 9 AUTHOR Morris DM AUTHOR Vuthiganon C AUTHOR Chang P AUTHOR Wiernik PH AUTHOR Elias EG TITLE Adriamycin in management of malignant hemangiopericytoma. SOURCE Am Surg; VOL 47, ISS 10, 1981, P441-6 5 AUTHOR Hou M AUTHOR Yu P AUTHOR Zhong YM AUTHOR Dong Y AUTHOR Chen Y TITLE Pharmacokinetics and clinical significance of adriamycin (ADR) after intravenous injection in different dosages SOURCE J. Chin. Pharm.; VOL 6 ISS 6 1995, P25-26, (REF 4) ABSTRACT IPA COPYRIGHT: ASHP To study the pharmacokinetics of doxorubicin (Adriamycin) after intravenous (IV) injection of different dosages, a study was conducted in 14 patients with malignant tumor who received an IV injection of doxorubicin 25 mg/m2 or 40 mg/m2. Results showed that peak concentration, AUC, and Vc were higher in the 40 mg/m2 group than those in the 25 mg/m2 group. The differences were statistically significant. The pharmacokinetics showed significant individual differences. The peak concentration and Vc correlated with curative effects. 7 AUTHOR Dutch expert committee on occupational standards TITLE Scientific documentation on the dutch list of occupational carcinogens (1). Adriamycin SOURCE Ministry of Social Affairs and Employment; RA 1/95; 1995; 6-7 ABSTRACT There is inadequate evidence that adriamycin is carcinogenic to human. The compound is carcinogenic to rats by i.v. and subcutaneous injections. It produced malignan tumours in the bladder after intravesical instillation. Adriamycin is mutagenic in bacteria and mammalian cells in vitro. The compound is classified as genotoxic carcinogen.